HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew Chase Selected Research

BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative)

9/2010Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.
11/2007A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
4/2005The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew Chase Research Topics

Disease

10Neoplasms (Cancer)
01/2019 - 10/2006
3Eosinophilia
01/2019 - 08/2002
3BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative)
09/2010 - 04/2005
3Hematologic Neoplasms (Hematological Malignancy)
09/2010 - 04/2005
2Genetic Translocation (Chromosomal Translocation)
01/2013 - 08/2002
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2010 - 04/2005
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2010 - 08/2002
1Disease Progression
02/2015
1Prostatic Neoplasms (Prostate Cancer)
05/2011
1Lymphoma (Lymphomas)
01/2010
1Myeloproliferative Disorders (Myeloproliferative Disorder)
01/2007
1Chromosome Aberrations (Chromosome Abnormalities)
01/2007
1Pdgfra-Associated Chronic Eosinophilic Leukemia
04/2005
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
04/2005
1Skin Diseases (Skin Disease)
08/2002
1Leukocytosis (Pleocytosis)
08/2002
1Residual Neoplasm
01/2002

Drug/Important Bio-Agent (IBA)

4Phosphotransferases (Kinase)IBA
09/2010 - 08/2002
4Imatinib Mesylate (Gleevec)FDA Link
01/2010 - 01/2002
3Tyrosine (L-Tyrosine)FDA Link
09/2010 - 10/2006
3Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
01/2010 - 08/2002
3Tyrosine Kinase InhibitorsIBA
11/2007 - 01/2002
2ruxolitinibIBA
02/2015 - 03/2013
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2015 - 09/2010
2Proteins (Proteins, Gene)FDA Link
01/2013 - 05/2008
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
01/2007 - 01/2002
1Polycomb Repressive Complex 2IBA
02/2012
1Histones (Histone)IBA
05/2011
13-deazaneplanocinIBA
05/2011
1Transcription Factors (Transcription Factor)IBA
09/2010
1Interferon-alpha (Interferon Alfa)IBA
01/2010
1InterferonsIBA
01/2010
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2010
1RNA Precursors (Precursor, mRNA)IBA
05/2008
14- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA
11/2007
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2007
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2007
1Pyridinolcarbamate (P23)IBA
04/2005
1AutoantigensIBA
04/2005

Therapy/Procedure

5Therapeutics
01/2019 - 10/2006
2Stem Cell Transplantation
02/2015 - 01/2002
2Aftercare (After-Treatment)
08/2002 - 01/2002
1Immunotherapy
11/2007